Lonza has bolstered its presence in the field of antibody-drug conjugates (ADC) by extending its manufacturing collaboration with a renowned biopharma company. This strategic move involves the expansion of its bioconjugation operations at the Ibex Biopark located in Visp, Switzerland. Under this
Roche's recent decision to return the rights to UCB’s anti-tau antibody bepranemab comes after a four-year investment in the Alzheimer's disease drug candidate, which was initially valued at up to $2 billion in milestones. This strategic move happens just before the release of phase 2a data for the
The modern biopharmaceutical industry is witnessing a significant transformation, thanks to the integration of artificial intelligence (AI) tools in early drug discovery. AI’s capabilities in managing and analyzing vast amounts of data generated from cell-based preclinical models through imaging
Charles River Laboratories has taken a significant stride in the realm of biopharmaceutical research by launching the Retrogenix Non-Human Protein Library. This innovation is particularly designed to help clients assess the off-target interactions of their therapeutics with non-human proteins. The
Are Biopharma Companies Ready for Today's Regulatory Challenges? The biopharmaceutical sector is rapidly evolving, with companies constantly innovating to develop new treatments for a variety of diseases. However, navigating the regulatory landscape remains a significant challenge. Stricter
RNA editing has long been a topic of fascination within the field of genetic research. Recent advancements by Wave Life Sciences have transformed this curiosity into a real-world application, with their trials showing promising results for treating alpha-1 antitrypsin deficiency (AATD). This
As the U.S. presidential election looms, the conversation around pharmaceutical policies intensifies, with Vice President Kamala Harris and former President Donald Trump proposing divergent paths. Harris and Trump represent fundamentally different approaches to drug pricing reforms, reflecting
The biotech industry is bustling with innovation and potential, and Xeris Biopharma Holdings Inc (NASDAQ: XERS) is making waves. This article aims to delve deep into the nuts and bolts of Xeris Biopharma’s recent market activities, financial health, insider trading, analysts' ratings, valuation
Lundbeck, the Danish drugmaker, has announced its acquisition of Longboard Pharmaceuticals for $2.6 billion, centering the deal around Longboard's promising experimental brain medicine, bexicaserin. This medicine is in late-stage clinical testing for treating developmental and epileptic
The biopharmaceutical industry is persistently advancing, fueled by innovations and strategic alliances designed to tackle some of the toughest medical challenges. A particularly promising collaboration that has emerged is the partnership between Matica Biotechnology Inc. (Matica Bio) and
